immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, has announced that Nature Medicine has published the key data covering the scientific and clinical development of its lead cancer vaccine, IMA901. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to more than one of the peptides in IMA901, the first multi-peptide therapeutic cancer vaccine for RCC.
IMA901 consists of 10 tumor-associated peptides (TUMAPs) confirmed to be naturally presented on tumour cells in patients with renal cell carcinoma (RCC). immatics identified, selected and validated the peptides in IMA901 using its proprietary XPRESIDENT platform, which has enabled a uniquely rational approach to cancer vaccine development.
The Nature Medicine paper reports the findings of two clinical trials with IMA901 in RCC patients. These results are the first showing that naturally presented TUMAPs are clinically relevant in the development of cancer vaccines and can produce meaningful outcomes. In contrast with a number of other cancer vaccine approaches, this research demonstrates that patients who mount a broad anti-tumour immune response experience extended survival.
In another key finding, the researchers identified two serum biomarkers which may help to determine which patients are most likely to achieve an overall survival benefit in future studies with IMA901. The current pivotal phase III trial with IMA901 aims to confirm that these two biomarkers are predictive of improved overall survival.
Dr Harpreet Singh, immatics’ Chief Scientific Officer and corresponding author of the publication, said: “Having these results published by Nature Medicine is recognition of the rationale behind our development of IMA901 and our other pipeline products. When we formed immatics we were clear that a rational approach to cancer vaccine development was crucial for success. We have been rigorous in following a highly systematic process to identify multiple relevant peptides from primary tumor tissues and then using immunomonitoring and biomarkers to generate and advance IMA901. This journey has produced several novel findings in the cancer immunotherapy field which we believe will advance the development of cancer vaccines and could change the way the disease is managed and treated.”
Paul Higham, immatics’ chief executive officer, said, “The potential of IMA901 to extend survival times for patients with renal cancer while offering a very good side effect profile is very exciting and offers the potential of real clinical benefit to patients with RCC. Our results so far illustrate the power of our rational approach to cancer vaccine development. We look forward to confirming the positive findings we have generated when we report the results from our on-going pivotal phase III trial with IMA901.”
The work was performed in close collaboration with a large number of academic institutions, foremost the University of Tuebingen, where the Department of Immunology ? led by Prof. Hans-Georg Rammensee, also the originator of the concept behind IMA901 and co-founder of immatics ? and the Department of Urology ? led by Prof. Arnulf Stenzl, also the Principal Investigator of both clinical trials described in this publication ? played a vital role.